To assess long-term efficacy & safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247).
Rotavirus Vaccine
Infections, Rotavirus
Phase 3
This is a follow-up study to 102247. An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number is not available for this study because the study was conducted before regulatory requirements to register studies.
January 2014